GlassScriptPhysician profile
Jack H Austin
NPI 1972612190
$5,222.29
in general payments reported to CMS, 2019-2025
28 companies · $96.59 in 2025
The $96.59 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $438 · 2021: $397 · 2022: $696 · 2023: $1,133 · 2024: $1,136 · 2025: $96.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $774.48 | 2019-2025 | Dificid, Delstrigo, Pifeltro |
| Insmed, INC. | $647.92 | 2019-2023 | Arikayce |
| Viiv Healthcare Company | $552.24 | 2019-2025 | Apretude, Dovato, Rukobia |
| Abbvie INC. | $537.82 | 2021-2024 | Avycaz, Teflaro, Dalvance |
| Melinta Therapeutics, LLC | $370.75 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Gilead Sciences, INC. | $264.47 | 2019-2024 | |
| Astellas Pharma US INC | $259.57 | 2019-2024 | Cresemba |
| Allergan, INC. | $232.41 | 2019-2020 | |
| Shionogi INC | $215.27 | 2023-2024 | Fetroja |
| Paratek Pharmaceuticals, INC. | $170.35 | 2020-2024 | Nuzyra |
| Octapharma USA, INC. | $164.07 | 2022-2024 | Panzyga |
| Pfizer INC. | $153.91 | 2020-2025 | |
| Tetraphase Pharmaceuticals, INC. | $152.04 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $102.48 | 2021-2024 | Xacduro |
| Ferring Pharmaceuticals INC. | $100.25 | 2023-2024 | Rebyota |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $98.91 | 2019-2023 | Symtuza |
| Polynovo North America LLC | $64.93 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.57 | 2023 | Cuvitru |
| Vbi Vaccine (Delaware) INC. | $46.52 | 2022-2023 | Prehevbrio |
| Amgen INC. | $43.27 | 2019 | |
| Pharming Healthcare, INC. | $40.86 | 2022-2024 | Ruconest |
| Glaxosmithkline, LLC. | $39.33 | 2024-2025 | Shingrix, Arexvy |
| Hospira, INC. | $38.18 | 2022-2023 | |
| Grifols USA, LLC | $35.86 | 2019-2024 | Xembify |
| Adma Biomanufacturing LLC | $18.93 | 2021 | |
| Theratechnologies INC. | $15.80 | 2023 | Trogarzo, Egrifta |
| Mayne Pharma Commercial LLC | $11.65 | 2020 | |
| Abbott Laboratories | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.